← All trials
NCT04594811
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 7, 2021
- Primary completion
- Nov 28, 2022
- Completion date
- May 29, 2023
- First posted
- Oct 20, 2020
- Last posted
- Dec 17, 2020
- Enrollment
- 145
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NeoImmuneTech, Inc.Lead sponsor
- Bristol-Myers SquibbCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.